Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Scientists used CRISPR technology to disable the cholesterol gene in a groundbreaking study, though widespread availability ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

Furthermore, it benefits from a strong competitive edge, thanks to its relationships with third-party payers, patients, and physicians. And with long-term trends like the world's aging population, ...

Across sectors, tech majors worldwide blurred the line between experimental and practical, pushing the world into a new phase ...

The findings might overturn a widely held belief that only females pose a disease risk to people, though more research is ...

Precise tumor diagnosis and treatment require the support of abundant molecular information. However, conventional molecular ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

SRINAGAR: SKUAST-K has secured a major scientific windfall, winning eight high-impact R&D projects worth Rs 7.22 crore from the Anusandhan National Research Foundation (ANRF). The funding, awarded ...

India's first gene-edited sheep recently turned a year old and researchers who developed it say it's doing well. Born on 16 ...